Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 221-229 , 1 March 2010

Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study

  • Ralitza Gueorguieva

      Affiliations

    • Yale University School of Public Health and School of Medicine, New Haven, CT 06520, USA
    • Corresponding Author InformationCorresponding author at: 60 College St., Room 215B, New Haven, CT 06520-8034, USA. Tel.: +1 203 974 7529; fax: +1 203 974 7662.
    • ,
  • Ran Wu

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Dennis Donovan

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA 98105, USA
    • ,
  • Bruce J. Rounsaville

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • David Couper

      Affiliations

    • Department of Biostatistics, The University of North Carolina at Chapel Hill, NC 27514, USA
    • ,
  • John H. Krystal

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • VA Connecticut Healthcare System, West Haven, CT 06516, USA
    • ,
  • Stephanie S. O’Malley

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA

Received 14 August 2009 ,Revised 28 October 2009 ,Accepted 28 October 2009.

References 

  1. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology. 2004;173(1–2):32–40
  2. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo controlled-placebo trial. Am. J. Psychiatry. 1999;156:1758–1765
  3. Anton RF, O’Malley SS, Ciraulo D, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017
  4. Babor TF, Longabaugh R, Zweben A, Fuller RK, Stout RL, Anton RF, et al. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J. Stud. Alcohol. Suppl. 1994;12:101–111
  5. Baros AM, Latham PK, Monk DH, Voronin K. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcohol Carroll. Clin. Exp. 2007;31:596–603
  6. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, et al. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo controlled trial. Arch. Gen. Psychiatry. 2004;64:264–272
  7. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin FH. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch. Gen. Psychiatry. 1994;51:989–997
  8. Chassin L, Pitts SC, Prost J. Binge drinking trajectories from adolescence to emerging adulthood in a high risk sample: predictors and substance abuse outcomes. J. Consult. Clin. Psychol. 2002;70(1):67–78
  9. Chung T, Maisto SA, Cornelius JR, Martin CS. Adolescents’ alcohol and drug use trajectories in the year following treatment. J. Stud. Alcohol. 2004;65(1):105–114
  10. Chung T, Maisto SA, Cornelius JR, Martin CS, Jackson KM. Joint trajectory analysis of treated adolescents’ alcohol use and symptoms over 1 year. Addict. Behav. 2005;30(9):1690–1701
  11. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6:566–573
  12. Dearing RL, Barrick C, Dermen KH, Wlitzer KS. Indicators of client engagement: influences on alcohol treatment satisfaction and outcomes. Psychol. Addict. Behav. 2005;19(1):71–78
  13. Del Boca FK, Darkes J, Greenbaum PE, Goldman MS. Up close and personal: temporal variability in the drinking of individual college students during their first year. J. Consult. Clin. Psychol. 2003;72(2):155–164
  14. Diggle PJ. Analysis of Longitudinal Data. Oxford: Clarendon Press; 1994;
  15. Dolan CV, Schmittman VR, Lubke GH, Neale MC. Regime switching in the latent growth curve mixture model. Struct. Eq. Model. 2005;12(1):94–120
  16. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. Combined acamprosate and naltrexone, with cognitive behavioral therapy is superior to either medication alone for alcohol abstinence: a single centres’ experience with pharmacotherapy. Alcohol. Alcohol. 2006;41:321–327
  17. Finney JW, Moyer A, Swearingen CE. Outcome variables and their assessment in alcohol treatment studies: 1968–1998. Alcohol Clin. Exp. Res. 2003;27(10):1671–1679
  18. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. A randomised control trial in community-based primary care practices. JAMA. 1997;277:1039–1045
  19. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA. 1986;256:1449–1455
  20. Greenbaum PE, Del Boca FK, Darkes J, Wang CP, Goldman MS. Variation in the drinking trajectories of freshmen college students. J. Consult. Clin. Psychol. 2004;73(2):229–238
  21. Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck R, O’Malley S, et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol. Psychiatry. 2007;61:1290–1295
  22. Hill KG, White HR, Chung IJ, Hawkins JD, Catalano RF. Early adult outcomes of adolescent binge drinking: person and variable-centered analyses of binge drinking trajectories. Alcohol. Clin. Exp. Res. 2000;24(6):892–901
  23. Hyytia P, Sinclair JD. Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol. Clin. Exp. Res. 1993;17(3):631–636
  24. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685
  25. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a multi-site randomized controlled trial. JAMA. 2007;298:1641–1651
  26. Jones B, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol. Methods Res. 2001;29(3):374–393
  27. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry. 2003;60:92–99
  28. King AC, Volpicelli JR, Frazer A, O’Brien CP. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl.). 1997;129(1):15–22
  29. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. 2001;25(9):1335–1341
  30. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley SS. Family history of alcoholism influences naltrexone-induced reductions in drinking. Biol. Psychiatry. 2007;62(6):694–697
  31. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. NEJM. 2001;345:1734–1739
  32. Lindsey JK. Models for Repeated Measurements. Oxford: Clarendon Press; 1993;
  33. Longabaugh, R., Zweben, A., LoCastro, J., WR, M., 2005. Origins, issues and options in the development of the Combined Behavioral Intervention. Journal of Studies on Alcohol 2005, 179–185.
  34. Longford NT. Random Coefficient Models. Oxford: Claredon Press; 1993;
  35. Mann K, Lehart P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol.: Clin. Exp. Res. 2004;28(1):51–63
  36. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J. Clin. Psychiatry. 2001;62(20):42–48
  37. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J. Stud. Alcohol. 2005;66(Suppl. 15):148–156
  38. In:  Miller WR editors. Combined Behavioral Intervention Manual: A Clinical Research Guide for Therapists Treating People with Alcohol Abuse and Dependence. vol. 1:Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004;
  39. Muthén BO, Muthén LK. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol. Clin. Exp. Res. 2000;24(6):882–891
  40. Muthén BO, Muthén LK. The development of heavy drinking and alcohol-related problems from ages 18 to 37 in a U.S. national sample. J. Stud. Alcohol. 2000;290–300
  41. Muthén BO. Mplus Technical Appendices. Los Angeles, CA: Muthén & Muthén; 2004;(Appendix 8)
  42. Nagin DS. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol. Methods. 1999;4(2):139–157
  43. Nagin DS, Tremblay RE. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol. Methods. 2001;6(1):18–34
  44. O’Malley SS, Jaffe AJ, Rode S, Rounsaville BJ. Experience of a “slip” among alcoholics treated with naltrexone or placebo. Am. J. Psychiatry. 1996;153(2):281–283
  45. O’Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch. Intern. Med. 2003;163(14):1695–1704
  46. O’Malley S, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol dependent women: a randomized, double-blind, placebo controlled trial. Alcohol.: Clin. Exp. Res. 2007;31(4):625–634
  47. Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006;26(6):610–625
  48. Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J. Stud. Alcohol. 2005;15:170–178
  49. Pettinati HM, Weiss RD, Miller WR, Donovan DM, Ernst DB, Rounsaville BJ. Medical Management (MM) Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. vol. 2. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004;
  50. Project MATCH Research Group . Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol. 1997;58:7–29
  51. Project MATCH Research Group . Project MATCH secondary a priori hypotheses. Addiction. 1997;92:1671–1698
  52. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd edition. Newbury Park, CA: Sage; 2002;
  53. Sinclair JD. Drugs to decrease alcohol drinking. Annals Int. Med. 1990;22:357–362
  54. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In:  Allen J,  Litten RZ editor. Measuring Alcohol Consumption: Psycosocial and Biological Methods. New Jersey: Human Press; 1992;
  55. Sobell LC, Sobell MB. Alcohol consumption measures. In:  Allen JP,  Columbus M editor. Assessing Alcohol Problems: A Guide for Clinician and Researchers. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1995;p. 55–73
  56. Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. Drugs RD. 2002;3(1):1–12
  57. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2005;8(2):267–280
  58. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry. 1994;151(10):1463–1467
  59. Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP. Effect of naltrexone on alcohol “high” in alcoholics. Am. J. Psychiatry. 1995;152(4):613–615
  60. Volpicelli JR, Rhimes KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry. 1997;54:737–742
  61. Wang SJ, Winchell CJ, McCormick S, Nevius E, O’Neill RT. Short of complete abstinence: an analysis exploration of multiple drinking episodes in alcoholism treatment trials. Alcohol. Clin. Exp. Res. 2002;26:1803–1809
  62. Witkiewitz K, van der Maas HJ, Hufford MR, Marlatt GA. Non-normality and divergence in post treatment alcohol use: re-examining the Project MATCH Data “Another Way”. J. Abnormal Psychol. 2007;116(2):378–394
  63. Zweben A, Pettinati HM, Weiss RD, Youngblood M, Cox CE, Mattson ME, et al. Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol.: Clin. Exp. Res. 2008;32(9):1661–1669

PII: S0376-8716(09)00407-4

doi: 10.1016/j.drugalcdep.2009.10.017

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 221-229 , 1 March 2010

Article Tools

* Image Usage & Resolution